EU/3/17/1945: Orphan designation for the treatment of Allan-Herndon-Dudley syndrome



On 12 October 2017, orphan designation (EU/3/17/1945) was granted by the European Commission to Medical Need Europe AB, Sweden, for tiratricol for the treatment of Allan-Herndon-Dudley syndrome.

Key facts

Active substance
Intended use
Treatment of Allan-Herndon-Dudley syndrome
Orphan designation status
EU designation number
Date of designation

Rare Thyroid Therapeutics International AB
Klara Norra Kyrkogata 26
Stockholms Domkyrkofors
111 22 Stockholm
Stockholms Lan

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Update history

The sponsor’s address was updated in April 2022.

The sponsorship was transferred to MN Development AB, Sweden, in May 2018.

In November 2018, MN Development AB changed name to Rare Thyroid Therapeutics.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating